FDA Urged To Moderate Evidence Requirements In LDT Framework
This article was originally published in The Gray Sheet
Executive Summary
The agency will need to restrain evidence expectations for proving clinical validity in its planned framework for regulating laboratory-developed tests in order to make the framework more feasible, speakers at a Sept. 18 Avalere conference said.